Hansa Biopharma Ab · OMXSTO:HNSA
Hansa Biopharma Ab — Investor Presentation (June 2026)
28 slides from Hansa Biopharma Ab's investor presentation, June 2026
Slide 1: Corporate Presentation June 2026
® Corporate Presentation June 2026
Slide 2: Forward-looking statements
Forward-looking statements ® This presentation may contain certain forward-looking statements and forecasts based on our current expectations and beliefs regarding future events and are subject to significant uncertainties and risks since they relate to events and depend on circumstances that will o
Slide 3: Novel, first-in-class IgG-cleaving enzyme from proprietary technology platform
Novel, first-in-class IgG-cleaving enzyme from proprietary technology platform ® What is IgG Hansa’s IgG-cleaving Platform Immunoglobulin G (IgG): a protective antibody Imlifidase – proprietary, first in class IgG cleaving enzyme Transplantation / Gene Therapy: High antibody (IgG) Rapid and ta
Slide 4: Unique platform targeting serious immune mediated conditions; rapid IgG reduction
Unique platform targeting serious immune mediated conditions; rapid IgG reduction ® Provides unmatched speed in reducing IgG IgG cleaving enzymes cleave antibodies across all domains Extravascular Cell bound IgG lowering Intravascular IgG IgG IgG modalities Imlifidase HNSA-5487 FcRn inhibitor - PLEX
Slide 5: Addressing orphan / rare indications
Addressing orphan / rare indications ® THERAPEUTIC FOCUS Desensitization Idefirix conditionally approved in EU & the UK For desensitization prior to kidney transplantation deceased donor Enabling Transplantation Paradigm shift for highly sensitized kidney transplant patients Out-licensing Agreement
Slide 6: Desensitization: Transplantation
® DESENSITIZATION Transplantation © 2026, Hansa Biopharma AB
Slide 7: Transplantation: High Unmet Need with Significant Market Potential
Transplantation: High Unmet Need with Significant Market Potential ® Imlifidase represents a pioneering Desensitization Potentially significantly larger breakthrough for highly sensitized TRANSPLANTATION population as not all patients are patients Potential market opportunity > $2bn referred to
Slide 8: Unmet need: Highly sensitized U.S. patients face indefinite dialysis
Unmet need: Highly sensitized U.S. patients face indefinite dialysis ® US Transplant Waitlist ~ 15% of patients are highly sensitized The US represents a significant (cPRA > 80%) market opportunity Significant ~100,000 on the wait list Unmet ~15k highly sensitized ~45,000 patients with Medical Need
Slide 9: Robust U.S. commercialization strategy established
Robust U.S. commercialization strategy established ® Concentrated Market Pricing and Reimbursement Experienced US Team ~200 adult transplant centers ~55% Medical Affairs paid by Medicare Focused field-based team with strong transplant market experience Market Access SVP Market Access with recent lau
Slide 10: Successful US ConfIdeS Phase 3 study
Successful US ConfIdeS Phase 3 study ® Highly statistically significant outcome (p<0.0001) Imlifidase Control Imlifidase Control p-value n n eGFR (mean) eGFR (mean) Primary endpoint 32 32 51.5 19.3 <0.0001 eGFR at 12 months in FAS Rank-based non-parametric analysis of eGFR at 32 32 50.0* 0* 0.0001 1
Slide 11: Long-term follow-up study showed durable graft and patient survival
Long-term follow-up study showed durable graft and patient survival ® Study Overview Extended pooled analysis from the 17-HMedIdeS-14 study A long-term follow-up study of patients who have received a kidney transplant following desensitization with imlifidase Key Takeaways (outcomes similar to n
Slide 12: Licensing Agreement for IDEFIRIX in EU, UK and MENA
® Licensing Agreement for IDEFIRIX in EU, UK and MENA Transplantation © 2026, Hansa Biopharma AB
Slide 13: Transaction Overview: €115 million licensing agreement for IDEFIRIX
Transaction Overview: ® €115 million licensing agreement for IDEFIRIX in Europe and MENA Transaction Scope Partnership Responsibilities Exclusive out-licensing of IDEFIRIX for transplantation in SERB Hansa EU, UK, Switzerland, Norway, Liechtenstein, Iceland and MENA to SERB. • Positive PAES topline
Slide 14: Estimated Financial Impact of €115 million licensing agreement
Estimated Financial Impact of €115 million licensing agreement for IDEFIRIX in Europe and MENA ® Cash Position o Transaction (upfront €110M or 1.3 BSEK) significantly increases Hansa’s cash position o Pro forma cash based on Q1 2026 cash on hand ~1.9 BSEK Pro Forma Q1 2026 Cash with Out Licensing Ag
Slide 15: Europe: Positive Data from Post Approval Confirmatory Study (PAES)
Europe: Positive Data from Post Approval Confirmatory Study (PAES) ® Current Status in Europe Next Step 50 highly sensitized patients Reimbursement Focus on business as usual until 23+ markets across the EU transplanted across 23 sites representing 90% of the closing of SERB Pharma Primary obj
Slide 16: Desensitization: Gene Therapy
® DESENSITIZATION Gene Therapy © 2026, Hansa Biopharma AB
Slide 17: Compelling opportunity in high-growth gene therapy sector
Compelling opportunity in high-growth gene therapy sector ® GENE THERAPY MARKET DESENSITIZATION Multiple gene therapy drugs SIGNIFICANT GROWTH EXPECTED GENE THERAPY with 10 - 40% of patients eligible who cannot be Existing $2B+ market in 2024 treated due to AAV vector Expected to reach $23.9B by 2
Slide 18: Collaborating to bridge access to gene therapies for more patients
Collaborating to bridge access to gene therapies for more patients ® Indication exclusivity Indication exclusivity Current Duchenne Muscular Crigler-Najjar syndrome – partnerships Dystrophy (DMD) - 1/3,500 to ultrarare condition with 5,000 male births worldwide approximate incidence is 0.6- 1 ca
Slide 19: Next generation Compound – Autoimmune Focus: HNSA-5487
® Next generation Compound – Autoimmune Focus HNSA-5487 © 2026, Hansa Biopharma AB
Slide 20: Non-human host derived; Phase 1 clinical data
Non-human host derived; Phase 1 clinical data ® Data demonstrated significantly lower immunogenicity for HNSA-5487 with rapid and robust IgG reduction – targeting FDA interaction in 1H 2026 for GBS Study Overview • Double blind, randomized, placebo-controlled trial in 36 healthy volunteers received
Slide 21: Phase 2 Study demonstrated the role imlifidase may play in halting GBS progression
Phase 2 Study demonstrated the role imlifidase may play in halting the progression of GBS ® Guillain-Barré Syndrome Phase 2 Study Results A rare, acute, paralyzing, inflammatory disease of the peripheral nervous system caused by the immune Rapid overall improvement in functional system damaging ne
Slide 22: Rare disease focus; IgG mediated conditions
Rare disease focus; IgG mediated conditions ® Guillan Barré Syndrome Significant unmet medical need – nothing approved in Europe and US Europe or the US for GBS 13,551 Strong Phase 2 data with imlifidase provides basis for addressable further clinical development 18,564 incidence FDA interaction in
Slide 23: Financials and Outlook
® FINANCIALS AND OUTLOOK © 2026, Hansa Biopharma AB
Slide 24: Company profile & financial highlights
Company profile & financial highlights ® Idefirix® conditionally European out licensing Ended Q1 2026 with 677 MSEK Headquartered in Lund, approved in Europe. Product transaction to SERB Pharma, in cash, (~ $73 M), proforma for Sweden with offices in sales grew by +46% in 2025, Euro 115 million valu
Slide 25: Validated, high value pipeline with transformative milestones ahead
Validated, high value pipeline with transformative milestones ahead ® Q1 2026 Q2 2026 Q3 2026 Q4 2026 BLA Potential US ATC US Filing for full acceptance approval/ ConfIdeS full approval with / PDUFA launch data EMA date presentation received GBS clinical development plan Topline data established Eur
Slide 26: Focused Pipeline in Desensitization and Autoimmune Diseases
® Focused Pipeline in Desensitization and Autoimmune Diseases Preclinical Phase 1 Phase 2 Phase 3 Marketed Partner Upcoming Milestone YE 2026: EMA filing for full marketing Desensitization Kidney Transplantation authorization Desensitization Kidney Transplantation PDUFA* date Dec 19, 2026 Desensitiz
Slide 27: Experienced and Proven Leadership Team
Experienced and Proven Leadership Team Proven track record delivering growth, approvals, and launches across renal, rare disease, and immunology ® Renée Aguiar-Lucander Maria Törnsén Chief Executive Officer Chief Operating Officer, President US 20+ yrs rare disease leader and former investor, Succes
Slide 28: HAN SAP
IZ HAN SAP BIOPHARMA